HETEROARYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS
申请人:Pfizer Products Inc.
公开号:EP1150973A1
公开(公告)日:2001-11-07
US6258824B1
申请人:——
公开号:US6258824B1
公开(公告)日:2001-07-10
US6388092B2
申请人:——
公开号:US6388092B2
公开(公告)日:2002-05-14
US6710209B2
申请人:——
公开号:US6710209B2
公开(公告)日:2004-03-23
[EN] HETEROARYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS<br/>[FR] DERIVES DE QUINOLIN-2-ONE A SUBSTITUTION HETEROARYLE CONVENANT COMME ANTI-CANCEREUX
申请人:PFIZER PROD INC
公开号:WO2000047574A1
公开(公告)日:2000-08-17
The present invention relates to compounds of formula (1) and pharmaceutically acceptable salts and solvates thereof wherein R?1, R2, R3, R4, R5, R6, R7, R8, R9¿, and Z are as defined herein. The invention also relates to pharmaceutical compositions comprising compounds of formula (1) and to methods of inhibiting abnormal cell growth, including cancer, in a mammal by administering compounds of formula (1) to the mammal. The invention also relates to intermediates and methods useful in synthesizing compounds of formula (1).